JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/gluc ...

SAFETY HARBOR, Fla., Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strategic and valuable Management Services Organization ("MSO") agreement with FDA licensed manufacturer of pharmaceutical products. This agreement enables MedWell USA to act as a Procurement Agent for Semaglutide, a leading pharmaceutical product in the weight management sector. MedWell USA will leverage various mar ...

关于活动 - 生命时光（Life Time）将于9月25日6:00 - 7:30 p.m. CT举办免费的GLP - 1信息直播小组活动可通过生命时光App观看 [1] - 活动将包含GLP - 1相关知识如它是什么如何工作适用人群等内容 [2] - 这是在长寿性能和抗衰老等领域计划的几个直播教育活动中的第一个 [2] 关于公司 - 生命时光（NYSE: LTH）通过在美国和加拿大的170多个运动乡村俱乐部组合让人们过上健康幸福的生活 [4] - 公司通过免费的生命时光数字应用程序提供一系列健康生活方式计划和信息 [4] - 公司的健康生活健康老龄化健康娱乐社区和生态系统为90天到90岁以上的人提供服务并有超过45000名专业人员支持 [4] - 公司除了通过俱乐部提供最好的项目和体验还拥有并举办近30个美国最具标志性的体育赛事 [4]

Terns has a modest market cap of less than $800 million, and its possible upside could be massive. Goldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, es ...

文章核心观点 - 尽管Hims & Hers的股价在过去一年经历了大幅波动,但公司的核心业务表现出色,Q2财报数据令人印象深刻[1][4][6] - 公司的GLP-1产品发布引发了市场的不确定性,但实际上应该被视为公司的一个强劲增长引擎[9][10] - 公司管理层表现出色,能够持续超越预期,并拥有良好的财务状况[3][5][6] 公司表现 - 公司自2020年通过SPAC上市以来,收入实现了10倍增长,从每季度3000万美元增长到3.15亿美元[4] - 公司预计2024年将实现首次净利润正值,并拥有健康的资产负债表,可以进行股票回购计划[5] - 公司Q2财报显示,净利润达1300万美元,EBITDA达3900万美元,订阅用户同比增长43%至190万[6] - 公司最新2024年全年指引为收入13.7-14亿美元,调整后EBITDA1.4-1.55亿美元,显示出公司持续超预期的能力[6] 行业机遇 - 全球远程医疗市场规模预计2024年达1010亿美元,未来6年将以24%的年复合增长率增长,为公司提供了广阔的增长空间[8] - 公司最近收购了一家FDA批准的复合药房,有望通过内部生产提高毛利率[11] - GLP-1产品的推出为公司带来了巨大的收入增长机会,尽管存在一些监管风险,但公司有信心应对[9][10] 潜在风险 - 亚马逊等大型公司可能会进入远程医疗市场,但这种"赢家通吃"的竞争场景是不太合理的[12][13] - 诺和诺德和礼来等制药公司可能会采取法律手段限制公司销售GLP-1产品,但公司有信心应对这一风险[14]

Omar Halawi/iStock via Getty Images I upgraded Becton, Dickinson and Company's (NYSE:BDX) to a 'Buy' rating in my previous article published in March 2024, arguing major growth challenges including Alaris pump and strong year-over-year comparables were fading away. I believe GLP-1 drug delivery could become a significant growth driver for the company in the near future. The company announced to acquire Edwards Lifesciences' (EW) Critical Care product group for $4.2 billion. I view the acquisition as value a ...

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher do ...

TAMPA, Fla., Sept. 4, 2024 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV), a holdings company, focused on e-commerce technology, digital assets and consumer-focused investments, is excited to announce (1) formation and launch of our second, fully funded, 100% owned subsidiary - MedWellDirect, LLC, Direct-ToConsumer (D2C) telemedicine solutions provider, mainly for weight loss and GLP-1 products and (2) acquisition of 51% stake in GetTrim.Com (TM), owned by Healthy Lifestyle USA – an innovative telem ...

文章核心观点 - 高蛋白饮食如凯托或肉食主义饮食正在成为一种自然的减重方法,因为它们可以缓解GLP-1减肥药物导致的肌肉流失问题 [1] - 在餐饮行业,增加牛肉菜品可以提高餐厅的销售业绩和利润率 [1] - 3家餐厅公司通过增加牛肉菜品实现了销售和利润的大幅增长 公司总结 1. Sweetgreen - 公司原本主打健康沙拉和餐碗,但增加牛肉菜品后吸引了更多肉食爱好者 [2][3] - 推出的"香蒜牛肉"菜品大受欢迎,在短时间内占到晚餐订单的1/5 [3] - 公司Q1和Q2的同店销售分别增长5%和9% [3] 2. CAVA Group - 公司经营地中海风格的自选餐碗,在Q2实现了14.4%的同店销售增长 [4][5] - 公司在2023年12月开始在波士顿测试牛肉菜品,反响良好,于2024年6月正式推出 [5] - 牛肉菜品推出后反响强烈,预计将在Q3财报中体现全面影响 [5] 3. Texas Roadhouse - 公司主营牛排餐厅,牛肉是其核心产品 [7] - 公司Q2同店销售增长9.3%,远超同行 [7] 4. Chili's Grill and Bar - 公司旗下Chili's餐厅的"大汉堡"菜品在社交媒体上走红,带动了14.8%的同店销售增长 [8][10] - 该菜品定价较低,与麦当劳等快餐形成直接竞争 [10]

Tim Platt/DigitalVision via Getty Images Thesis Viking Therapeutics (NASDAQ:VKTX) is a biotechnology company in the clinical stage focused on the discovery and development of novel treatments for metabolic and endocrinology disorders. Viking's most promising program is VK2735, a dual agonist (activator) of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is aimed for the treatment of obesity, and it accounts for two formulations currently being tested ...